Search

Your search keyword '"Li, Nannan"' showing total 1,071 results
Start Over Author "Li, Nannan" Publication Type Academic Journals
1,071 results on '"Li, Nannan"'

16. Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review

Author

Li, Nannan, Beaudart, Charlotte, Cauley, Jane A, Ing, Steven W, Lane, Nancy E, Reginster, Jean-Yves, Silverman, Stuart, Singer, Andrea J, and Hiligsmann, Mickaël

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Sciences, Comparative Effectiveness Research, Aging, Behavioral and Social Science, Osteoporosis, Clinical Research, Cost Effectiveness Research, Health Services, Prevention, Musculoskeletal, Male, Female, Humans, Middle Aged, Aged, Osteoporosis, Postmenopausal, Cost-Effectiveness Analysis, Osteoporotic Fractures, Diphosphonates, Cost-Benefit Analysis, Bone Density Conservation Agents, Medical and Health Sciences, Economics, Health Policy & Services, Pharmacology and pharmaceutical sciences, Applied economics, Health services and systems
Abstract

BackgroundOsteoporosis is often considered to be a disease of women. Over the last few years, owing to the increasing clinical and economic burden, the awareness and imperative for identifying and managing osteoporosis in men have increased substantially. With the approval of agents to treat men with osteoporosis, more economic evaluations have been conducted to assess the potential economic benefits of these interventions. Despite this concern, there is no specific overview of cost-effectiveness analyses for the treatment of osteoporosis in men.ObjectivesThis study aims (1) to systematically review economic evaluations of interventions for osteoporosis in men; (2) to critically appraise the quality of included studies and the source of model input data; and (3) to investigate the comparability of results for studies including both men and women.MethodsA literature search mainly using MEDLINE (via Ovid) and Embase databases was undertaken to identify original articles published between 1 January, 2000 and 30 June, 2022. Studies that assessed the cost effectiveness of interventions for osteoporosis in men were included. The Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and the International Osteoporosis Foundation osteoporosis-specific guideline was used to assess the quality of design, conduct, and reporting of included studies.ResultsOf 2973 articles identified, 25 studies fulfilled the inclusion criteria, classified into economic evaluations of active drugs (n = 8) or nutritional supplements (n = 4), intervention thresholds (n = 5), screening strategies (n = 6), and post-fracture care programs (n = 2). Most studies were conducted in European countries (n = 15), followed by North America (n = 9). Bisphosphonates (namely alendronate) and nutritional supplements were shown to be generally cost effective compared with no treatment in men over 60 years of age with osteoporosis or prior fractures. Two other studies suggested that denosumab was cost effective in men aged 75 years and older with osteoporosis compared with bisphosphates and teriparatide. Intervention thresholds at which bisphosphonates were found to be cost effective varied among studies with a 10-year probability of a major osteoporotic fracture that ranged from 8.9 to 34.2% for different age categories. A few studies suggested cost effectiveness of screening strategies and post-fracture care programs in men. Similar findings regarding the cost effectiveness of drugs and intervention thresholds in women and men were captured, with slightly greater incremental cost-effectiveness ratios in men. The quality of the studies included had an average score of 18.8 out of 25 (range 13-23.5). Hip fracture incidence and mortality risk were mainly derived from studies in men, while fracture cost, treatment efficacy, and disutility were commonly derived from studies in women or studies combining both sexes.ConclusionsAnti-osteoporosis drugs and nutritional supplements are generally cost effective in men with osteoporosis. Screening strategies and post-fracture care programs also showed economic benefits for men. Cost-effectiveness and intervention thresholds were generally similar in studies conducted in both men and women, with slightly greater incremental cost-effectiveness ratios in men.

Published
2023

17. Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review

Author

Li, Nannan, Beaudart, Charlotte, Cauley, Jane A, Ing, Steven W, Lane, Nancy E, Reginster, Jean‑Yves, Silverman, Stuart, Singer, Andrea J, and Hiligsmann, Mickaël

Subjects
Economics, Biomedical and Clinical Sciences, Applied Economics, Clinical Sciences, Medical and Health Sciences, Health Policy & Services, Pharmacology and pharmaceutical sciences, Applied economics, Health services and systems
Abstract

In the sentence beginning ‘However, it should be noted that updates to...’ under heading Methods, section 2.1, the text ‘these two databases were discontinued in 2015 and 2018, respectively’ should have read ‘National Health Service Economic Evaluation database were discontinued in 2015’. The complete sentence should read: However, it should be noted that updates to National Health Service Economic Evaluation database were discontinued in 2015. The original article has been corrected.

Published
2023

37. LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer

Author

Wu Tieqiu, Li Nannan, Wu Xinghui, Du Yongchao, and Tang Zhiwang

Subjects
bladder cancer, linc00592, wif1, promoter, methylation, Medicine
Abstract

Epigenetic alteration is a key feature that contributes to the progression of bladder cancer (BC) and long non-coding RNAs serve crucial role in the epigenetic modulation. This study was designed to explore the epigenetic regulation of LINC00592 in BC. LINC00592 expression in BC was examined. Then, LINC00592 was silenced in BC cell followed by cell behavior analyses using CCK-8, transwell, western blot, or flow cytometry. Potential downstream target of LINC00592 was explored using RNA pull-down assay and methylation of WIF1 was determined using methylated-specific PCR. In addition, WIF1 or/and LINC00592 were silenced in BC cells followed by cell behavior analyses to explore the regulation between them. Upregulation of LINC00592 was significantly detected in BC tissues and cells. In BC cells silencing LINC00592 suppressed the proliferation, migration, and epithelial-mesenchymal transitions (EMT), but enhanced apoptosis. Moreover, LINC00592 recruited DNMT1, DNMT3A, and DNMT3B to enhance WIF1 promoter methylation. In addition, WIF1 overexpression suppressed the proliferation, migration, as well as EMT, but enhanced apoptosis. Silencing WIF1 significantly attenuated the role of silencing LINC00592 in suppressing the proliferative, migratory, and EMT ability of BC cells, and increasing the apoptosis. LINC00592 promoted the growth and metastasis of BC via enhancing the promoter methylation of WIF1 and decreasing WIF1 transcription.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results